لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Drew AE; Epizyme, Inc., Cambridge, Massachusetts, USA. adrew@epizyme.com., Moradei O; Epizyme, Inc., Cambridge, Massachusetts, USA., Jacques SL; Epizyme, Inc., Cambridge, Massachusetts, USA., Rioux N; Epizyme, Inc., Cambridge, Massachusetts, USA., Boriack-Sjodin AP; Epizyme, Inc., Cambridge, Massachusetts, USA., Allain C; Epizyme, Inc., Cambridge, Massachusetts, USA., Scott MP; Epizyme, Inc., Cambridge, Massachusetts, USA., Jin L; Epizyme, Inc., Cambridge, Massachusetts, USA., Raimondi A; Epizyme, Inc., Cambridge, Massachusetts, USA., Handler JL; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Ott HM; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Kruger RG; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., McCabe MT; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Sneeringer C; Epizyme, Inc., Cambridge, Massachusetts, USA., Riera T; Epizyme, Inc., Cambridge, Massachusetts, USA., Shapiro G; Epizyme, Inc., Cambridge, Massachusetts, USA., Waters NJ; Epizyme, Inc., Cambridge, Massachusetts, USA., Mitchell LH; Epizyme, Inc., Cambridge, Massachusetts, USA., Duncan KW; Epizyme, Inc., Cambridge, Massachusetts, USA., Moyer MP; Epizyme, Inc., Cambridge, Massachusetts, USA., Copeland RA; Epizyme, Inc., Cambridge, Massachusetts, USA., Smith J; Epizyme, Inc., Cambridge, Massachusetts, USA., Chesworth R; Epizyme, Inc., Cambridge, Massachusetts, USA., Ribich SA; Epizyme, Inc., Cambridge, Massachusetts, USA.

المصدر: Scientific reports [Sci Rep] 2017 Dec 21; Vol. 7 (1), pp. 17993. Date of Electronic Publication: 2017 Dec 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , CARD Signaling Adaptor Proteins/*antagonists & inhibitors , Enzyme Inhibitors/*therapeutic use , Guanylate Cyclase/*antagonists & inhibitors , Isoxazoles/*therapeutic use , Multiple Myeloma/*drug therapy , Pyrimidines/*therapeutic use , Spiro Compounds/*therapeutic use, Animals ; Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/pharmacokinetics ; Humans ; In Vitro Techniques ; Isoxazoles/pharmacokinetics ; Male ; Mice ; Neoplasm Transplantation ; Pyrimidines/pharmacokinetics ; Rats, Sprague-Dawley ; Spiro Compounds/pharmacokinetics

المؤلفون: Ott HM; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Graves AP; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Pappalardi MB; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Huddleston M; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Halsey WS; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Hughes AM; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Groy A; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dul E; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Jiang Y; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Bai Y; Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Annan R; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Verma SK; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Knight SD; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Kruger RG; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dhanak D; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Schwartz B; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Tummino PJ; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Creasy CL; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., McCabe MT; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. michael.t.mccabe@gsk.com.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 3062-73. Date of Electronic Publication: 2014 Sep 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Mutation*, Histones/*metabolism , Polycomb Repressive Complex 2/*genetics , Polycomb Repressive Complex 2/*metabolism, Amino Acid Sequence ; Amino Acid Substitution ; Binding Sites ; Cell Line, Tumor ; Cluster Analysis ; Enhancer of Zeste Homolog 2 Protein ; Gene Expression ; Gene Expression Profiling ; Gene Silencing ; Heterozygote ; Humans ; Lysine/metabolism ; Methylation ; Models, Molecular ; Molecular Sequence Data ; Polycomb Repressive Complex 2/chemistry ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Protein Conformation ; Sequence Alignment ; Substrate Specificity ; Transcriptional Activation

المؤلفون: Van Aller GS; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D and ‡Platform Technology and Sciences, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, United States., Pappalardi MB, Ott HM, Diaz E, Brandt M, Schwartz BJ, Miller WH, Dhanak D, McCabe MT, Verma SK, Creasy CL, Tummino PJ, Kruger RG

المصدر: ACS chemical biology [ACS Chem Biol] 2014 Mar 21; Vol. 9 (3), pp. 622-9. Date of Electronic Publication: 2013 Dec 31.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101282906 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1554-8937 (Electronic) Linking ISSN: 15548929 NLM ISO Abbreviation: ACS Chem Biol Subsets: MEDLINE

مواضيع طبية MeSH: Enzyme Inhibitors/*pharmacology , Indoles/*pharmacology , Polycomb Repressive Complex 2/*antagonists & inhibitors , Pyridones/*pharmacology, Allosteric Regulation ; Allosteric Site ; Binding, Competitive ; Dose-Response Relationship, Drug ; Enhancer of Zeste Homolog 2 Protein ; Enzyme Inhibitors/chemistry ; HeLa Cells ; Humans ; Indoles/chemistry ; Methylation ; Nucleosomes/drug effects ; Nucleosomes/enzymology ; Point Mutation ; Polycomb Repressive Complex 2/genetics ; Protein Binding ; Pyridones/chemistry ; Structure-Activity Relationship ; Substrate Specificity ; Time Factors

المؤلفون: Béguelin W; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA., Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM

المصدر: Cancer cell [Cancer Cell] 2013 May 13; Vol. 23 (5), pp. 677-92.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: Mutation*, B-Lymphocytes/*metabolism , Cell Transformation, Neoplastic/*genetics , Germinal Center/*metabolism , Polycomb Repressive Complex 2/*physiology, Animals ; Cell Differentiation ; Cell Proliferation ; Enhancer of Zeste Homolog 2 Protein ; Gene Deletion ; Gene Expression Regulation, Neoplastic ; Germinal Center/drug effects ; Histones/metabolism ; Methylation ; Mice ; Polycomb Repressive Complex 2/genetics ; Polycomb Repressive Complex 2/metabolism ; Promoter Regions, Genetic ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Proto-Oncogene Proteins c-bcl-2/physiology

المؤلفون: McCabe MT; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, USA., Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL

المصدر: Nature [Nature] 2012 Dec 06; Vol. 492 (7427), pp. 108-12. Date of Electronic Publication: 2012 Oct 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

مواضيع طبية MeSH: Indoles/*pharmacology , Indoles/*therapeutic use , Lymphoma, Follicular/*drug therapy , Lymphoma, Large B-Cell, Diffuse/*drug therapy , Mutation/*genetics , Polycomb Repressive Complex 2/*antagonists & inhibitors , Pyridones/*pharmacology , Pyridones/*therapeutic use, Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Enhancer of Zeste Homolog 2 Protein ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Silencing/drug effects ; Histone Methyltransferases ; Histone-Lysine N-Methyltransferase/antagonists & inhibitors ; Histone-Lysine N-Methyltransferase/genetics ; Histone-Lysine N-Methyltransferase/metabolism ; Histones/chemistry ; Histones/metabolism ; Humans ; Lymphoma, Follicular/enzymology ; Lymphoma, Follicular/genetics ; Lymphoma, Follicular/pathology ; Lymphoma, Large B-Cell, Diffuse/enzymology ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/pathology ; Methylation/drug effects ; Mice ; Neoplasm Transplantation ; Polycomb Repressive Complex 2/genetics ; Polycomb Repressive Complex 2/metabolism ; Repressor Proteins/chemistry ; Repressor Proteins/metabolism ; Transcriptional Activation/drug effects ; Transplantation, Heterologous

المؤلفون: Verma SK; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Tian X; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., LaFrance LV; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Duquenne C; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Suarez DP; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Newlander KA; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Romeril SP; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Burgess JL; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Grant SW; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Brackley JA; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Graves AP; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Scherzer DA; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Shu A; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Thompson C; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Ott HM; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Aller GS; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Machutta CA; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Diaz E; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Jiang Y; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Johnson NW; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Knight SD; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Kruger RG; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., McCabe MT; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Dhanak D; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Tummino PJ; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Creasy CL; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States., Miller WH; Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States.

المصدر: ACS medicinal chemistry letters [ACS Med Chem Lett] 2012 Oct 19; Vol. 3 (12), pp. 1091-6. Date of Electronic Publication: 2012 Oct 19 (Print Publication: 2012).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101521073 Publication Model: eCollection Cited Medium: Print ISSN: 1948-5875 (Print) Linking ISSN: 19485875 NLM ISO Abbreviation: ACS Med Chem Lett Subsets: PubMed not MEDLINE

المؤلفون: McCabe MT; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology Research and Development, GlaxoSmithKline, Collegeville, PA 19426, USA. michael.t.mccabe@gsk.com, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, Smitheman KN, Ott HM, Pappalardi MB, Allen KE, Chen SB, Della Pietra A 3rd, Dul E, Hughes AM, Gilbert SA, Thrall SH, Tummino PJ, Kruger RG, Brandt M, Schwartz B, Creasy CL

المصدر: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2012 Feb 21; Vol. 109 (8), pp. 2989-94. Date of Electronic Publication: 2012 Feb 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

مواضيع طبية MeSH: Alanine/*genetics , DNA-Binding Proteins/*genetics , Histones/*metabolism , Lymphoma, B-Cell/*enzymology , Lymphoma, B-Cell/*genetics , Lysine/*metabolism , Mutation/*genetics , Transcription Factors/*genetics, Amino Acid Sequence ; Base Sequence ; Binding Sites ; Cell Line, Tumor ; DNA Mutational Analysis ; DNA-Binding Proteins/chemistry ; DNA-Binding Proteins/metabolism ; Enhancer of Zeste Homolog 2 Protein ; Gene Expression Regulation, Neoplastic ; Glycine/genetics ; Heterozygote ; Histone Methyltransferases ; Histone-Lysine N-Methyltransferase/chemistry ; Histone-Lysine N-Methyltransferase/genetics ; Histone-Lysine N-Methyltransferase/metabolism ; Humans ; Methylation ; Molecular Sequence Data ; Mutant Proteins/chemistry ; Mutant Proteins/metabolism ; Polycomb Repressive Complex 2 ; Substrate Specificity ; Transcription Factors/chemistry ; Transcription Factors/metabolism